Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan W Day

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Oncogene|November 7, 2024
EphA2 regulates vascular permeability and prostate cancer metastasis via modulation of cell junction protein phosphorylationCarolin Offenhäuser, Keyur A Dave, Kirrilee J Beckett, et al.
Neuro-Oncology|August 18, 2011
ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1Bryan W Day, Brett W Stringer, Mark D Spanevello, et al.
Neuro-Oncology|July 7, 2021
A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastomaObada T Alhalabi, Michael N C Fletcher, Thomas Hielscher, et al.
Cancers|November 13, 2013
Glioma surgical aspirate: a viable source of tumor tissue for experimental researchBryan W Day, Brett W Stringer, John Wilson, et al.
Nature Communications|March 14, 2020
Digenic inheritance of mutations in EPHA2 and SLC26A4 in Pendred syndromeMengnan Li, Shin-Ya Nishio, Chie Naruse, et al.
Cancer Letters|September 27, 2024
Integration of transcriptomics, proteomics and loss-of-function screening reveals WEE1 as a target for combination with dasatinib against proneural glioblastomaObada T Alhalabi, Mona Göttmann, Maxwell P Gold, et al.
Scientific Reports|March 22, 2019
A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastomaBrett W Stringer, Bryan W Day, Rochelle C J D'Souza, et al.
Scientific Reports|January 23, 2020
Publisher Correction: A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastomaBrett W Stringer, Bryan W Day, Rochelle C J D'Souza, et al.
Cancer Cell|February 16, 2013
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiformeBryan W Day, Brett W Stringer, Fares Al-Ejeh, et al.
Clinical & Translational Immunology|October 21, 2020
Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapyLisa M Ebert, Wenbo Yu, Tessa Gargett, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Oncogene|November 7, 2024
EphA2 regulates vascular permeability and prostate cancer metastasis via modulation of cell junction protein phosphorylationCarolin Offenhäuser, Keyur A Dave, Kirrilee J Beckett, et al.
Neuro-Oncology|August 18, 2011
ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1Bryan W Day, Brett W Stringer, Mark D Spanevello, et al.
Neuro-Oncology|July 7, 2021
A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastomaObada T Alhalabi, Michael N C Fletcher, Thomas Hielscher, et al.
Cancers|November 13, 2013
Glioma surgical aspirate: a viable source of tumor tissue for experimental researchBryan W Day, Brett W Stringer, John Wilson, et al.
Nature Communications|March 14, 2020
Digenic inheritance of mutations in EPHA2 and SLC26A4 in Pendred syndromeMengnan Li, Shin-Ya Nishio, Chie Naruse, et al.
Cancer Letters|September 27, 2024
Integration of transcriptomics, proteomics and loss-of-function screening reveals WEE1 as a target for combination with dasatinib against proneural glioblastomaObada T Alhalabi, Mona Göttmann, Maxwell P Gold, et al.
Scientific Reports|March 22, 2019
A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastomaBrett W Stringer, Bryan W Day, Rochelle C J D'Souza, et al.
Scientific Reports|January 23, 2020
Publisher Correction: A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastomaBrett W Stringer, Bryan W Day, Rochelle C J D'Souza, et al.
Cancer Cell|February 16, 2013
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiformeBryan W Day, Brett W Stringer, Fares Al-Ejeh, et al.
Clinical & Translational Immunology|October 21, 2020
Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapyLisa M Ebert, Wenbo Yu, Tessa Gargett, et al.
Pageof 8